Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Abstract Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mark C. Liu, Bradley Chipps, Xavier Munoz, Gilles Devouassoux, Miguel Bergna, Steven G. Smith, Robert G. Price, Dmitry V. Galkin, Jay Azmi, Dalal Mouneimne, Frank C. Albers, Kenneth R. Chapman
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2021-05-01
Serija:	Respiratory Research
Teme:	Asthma Asthma treatment Biologics Eosinophils
Online dostop:	https://doi.org/10.1186/s12931-021-01733-9
Oznake:	Označite Brez oznak, prvi označite!